REFERENCES
- Biederman J., Swanson J. M., Wigal S. B., Kratochvil C. J., Boellner S. W., Earl C. Q., et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116(6)777–784
- Black J. E., Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep. 2005; 287: 464–471
- Boschert S. Sadness alters tx for depression-related fatigue. Clinical Psychiatry News 2006; 34: 1–59
- Cephalon Inc. Provigil product information and medication guide. December, 2004, (U.S. Patent Nos. RE37,516 / 4,927,855 PROV-009)
- Chou T. C., Alvhild A., Bjorkum A. A., Gaus S. E., Lu J., Scammell T. E., et al. Afferents to the ventrolateral preoptic nucleus. The Journal of Neuroscience 2002; 22(3)977–990
- Damian M. S., Gerlach A., Schmidt F., Lehmann E., Reichmann H. Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001; 56(6)794–796
- DeBattista C., Doghramji K., Menza M. A., Rosenthal M. H., Fieve R. R. Journal of Clinical Psychiatry 2003; 64(9)1057–1064
- Engber T. M., Dennis S. A., Jones B. E., Miller M. S., Contreras P. C. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: Comparison with amphetamine. Neuroscience. 1998; 87: 905–911
- Food and Drug Administration. January 14, 2002, http://www.modafinil.com/fda/index.html FDA Warning Letter: RE: NDA #20-717, Provigil (Modafinil) Tablets. Retrieved August 17, 2006, from
- Happe S., Pirker W., Sauter C., Klosch G., Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. Journal of Neurology 2001; 248(7)632–634
- Ishizuka T., Sakamoto Y., Sakurai T., Yamatodani A. Modafinil increases histamine release in the anterior hypothalamus of rats. Neuroscience Letters 2003; 339(2)143–146
- Jasinski D. R., Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clinical Neuropharmacology. 2000; 23: 149–156
- Johns M. W. A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale. Sleep. 1991; 14: 540–545
- Krupp L. B., Christodoulou C. Fatigue in multiple sclerosis. Current Neurology & Neuroscience Reports 2001; 1(3)294–298
- Lin J. S., Hou Y., Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proceedings of the National Academy of Sciences USA 1996; 93: 14128–14133
- Ninan P. T., Hasman H. A., Glass S. J., McManus F. C. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. Journal of Clinical Psychiatry 2004; 65(3)414–420
- Saper C. B., Scammell T. E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005; 437: 1257–1264
- Shelton J., Nishino S., Vaught J., Dement W. C., Mignot E. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep. 1995; 18: 817–826
- Stahl S. Essential psychopharmacology of depression and bipolar disorder. Cambridge University Press, New York 2000
- Stahl S. Illustrated insights in sleep: Excessive sleepiness. NEI Press, San Diego 2005
- Stahl S. Essential psychopharmacology: The prescriber's guide, rev. ed. Cambridge University Press, New York 2006
- Tietelman E. Off-label uses of modafinil. American Journal of Psychiatry 2001; 158(8)1341